- PDE10 MODULATORS
-
The present invention relates to compounds of formula (I) wherein R1, R2, R3, R5, W, X, X1, Y, Y1, Z and Z1 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit PDE10A and can be used in the treatment of CNS disorders such as schizophrenia, Alzheimer's disease, and Parkinson's disease.
- -
-
Paragraph 0500-0501
(2013/03/26)
-
- PDE10 MODULATORS
-
The present invention relates to compounds of formula (I) wherein R1, R2, R3, R5, W, X, X1, Y, Y1, Z and Z1 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit PDE10A and can be used as medicaments.
- -
-
Page/Page column 85-86
(2013/03/26)
-
- 2-TRIFLUOROMETHYLIMIDAZOLE, 2,4,5-TRIS(TRIFLUOROMETHYL)IMIDAZOLE AND RELATED COMPOUNDS
-
2-Trifluoromethylimidazole, prepared by the reaction of imidazole-2-carboxylic acid with sulphur tetrafluoride, afforded a silver salt which reacted with organohalides (bromomethane, ethyl bromoacetate, N,N-dimethyl-2-chloroethylamine, and chloroacetonitrile) to give the corresponding N-alkylated derivatives. 2-Trifluoromethylimidazole-4,5-dicarboxylic acid was obtained by oxidation of 2-trifluoromethylbenzimidazole, and on decarboxylation gave only traces of 2-trifluoromethylimidazole; the major product was 2-trifluoromethylimidazole-4-carboxylic acid.The di-acid and sulphur tetrafluoride gave 2,4,5-tris(trifluoromethyl)imidazole.
- Owen, D.,Plevey, R. G.,Tatlow, J. C.
-
p. 179 - 186
(2007/10/02)
-